News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

RyMed Technologies Receives CE Mark, ISO and Canada Certification


5/29/2013 7:21:39 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

RyMed Technologies Receives CE Mark, ISO and Canada Certification

FRANKLIN, Tenn.--(BUSINESS WIRE)-- RyMed Technologies today announced it has received three major certifications that will allow the company to substantially expand its IV safety business worldwide.

RyMed has received a CE Mark, Health Canada validation for its quality management systems, and International Organization for Standardization (ISO) certification. The trio of highly prized certificates cover the quality assurance systems for manufacture of all the company’s intravenous needleless connectors, stopcocks and related intravenous extension and administration sets.

RyMed’s IV products for central venous (CVC) and peripherally inserted central catheters (PICCs) address a substantial market worldwide. Analyst estimates place the size of the global market for CVCs at more than $582 million annually. CVCs and PICCs in the U.S. and many other countries typically require a needleless IV connector such as RyMed’s flagship InVision-Plus®.

“The awarding of these three major certifications validates our quality management programs and opens up many more international markets for us, said Dana Wm. Ryan, President, CEO and Chairman of the Board of RyMed Technologies. “This is a huge opportunity for our zero fluid displacement technology, and a milestone on the path to much broader global adoption of our products.”

About RyMed Technologies, Inc.

Founded in 1994, RyMed Technologies specializes in the development and marketing of innovative safety products in the field of intravenous catheter care management. The company’s products are designed to help reduce catheter occlusion, catheter-related infections, and biofilm development commonly associated with vascular access devices. More than 10 years of research and development have gone into the InVision-Plus product line. Numerous studies regarding the efficacy of the InVision-Plus Needleless IV Connector have been published in the last six years—which is particularly important in light of the growing incidence of central line associated bloodstream infections (CLABSI).

For more information on the product and published studies, access www.rymedtech.com or call (615) 790-8093. The company is headquartered in Franklin, Tenn.

Contact:

Dowling & Dennis Public Relations

Liz Dowling, 415-388-2794

Liz@DowlingDennis.net



Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES